School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
J Control Release. 2017 Aug 28;260:202-212. doi: 10.1016/j.jconrel.2017.06.003. Epub 2017 Jun 8.
The poor solubility of significant number of Active Pharmaceutical Ingredients (APIs) has become a major challenge in the drug development process. Drugs with poor solubility are difficult to formulate by conventional methods and often show poor bioavailability. In the last decade, attention has been focused on developing nanocrystals for poorly water soluble drugs using nanosizing techniques. Nanosizing is a pharmaceutical process that changes the size of a drug to the sub-micron range in an attempt to increase its surface area and consequently its dissolution rate and bioavailability. The effectiveness of nanocrystal drugs is evidenced by the fact that six FDA approved nanocrystal drugs are already on the market. The bioavailabilities of these preparations have been significantly improved compared to their conventional dosage forms. There are two main approaches for preparation of drug nanocrystals; these are the top-down and bottom-up techniques. Top-down techniques have been successfully used in both lab scale and commercial scale manufacture. Bottom-up approaches have not yet been used at a commercial level, however, these techniques have been found to produce narrow sized distribution nanocrystals using simple methods. Bottom-up techniques have been also used in combination with top-down processes to produce drug nanoparticles. The main aim of this review article is to discuss the various methods for nanosizing drugs to improve their bioavailabilities.
大量的活性药物成分(APIs)溶解度差,已成为药物开发过程中的主要挑战。溶解度差的药物难以通过常规方法进行制剂,并且通常表现出较差的生物利用度。在过去十年中,人们一直关注使用纳米细化技术为难溶性药物开发纳米晶体。纳米细化是一种药物处理方法,它将药物的尺寸缩小到亚微米范围,试图增加其表面积,从而提高其溶解速率和生物利用度。纳米晶体药物的有效性已经得到了证实,因为已经有六种 FDA 批准的纳米晶体药物已经上市。与传统剂型相比,这些制剂的生物利用度有了显著提高。制备药物纳米晶体有两种主要方法;自上而下和自下而上的技术。自上而下的技术已成功应用于实验室规模和商业规模的制造。然而,自下而上的方法尚未在商业水平上使用,但这些技术已被发现可使用简单的方法生产出尺寸分布较窄的纳米晶体。自下而上的技术也已与自上而下的工艺结合使用,以生产药物纳米颗粒。本文的主要目的是讨论各种纳米药物的方法,以提高其生物利用度。